PURPOSE: Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase have demonstrated modest anticancer activity in advanced bronchioloalveolar carcinoma (BAC). We conducted a phase II study to evaluate cetuximab for the treatment of advanced BAC. PATIENTS AND METHODS: Patients with advanced-stage pure BAC or adenocarcinoma with BAC features, fewer than two prior chemotherapy regimens, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 were eligible. Those with prior EGFR inhibitor therapy were excluded. Cetuximab was given as a weekly intravenous infusion at 250 mg/m(2) after an initial loading dose of 400 mg/m(2) in week 1. The primary end point was determination of response rate. EGFR and KRAS mutations were evaluated by pyrosequencing. RESULTS: Seventy-two patients were enrolled and 68 met eligibility requirements. Characteristics of patients included median age, 71 years; sex, 57% females; PS 0 or 1, 88% of patients; and smoking status, 19% never-smokers. Central pathology review confirmed the diagnosis in 45 of 49 available specimens. Approximately 50% of patients received more than two cycles of therapy (> 8 weeks). Skin rash was the most common toxicity (grade 3, 15%). The confirmed response rate was 7%, and stable disease was observed in 35%. The median survival and progression-free survival were 13 and 3.3 months, respectively. Only one of the six patients with an EGFR mutation and one of the seven patients with a KRAS mutation had a partial response. CONCLUSION: Cetuximab was associated with modest efficacy in patients with advanced BAC, despite a low response rate. EGFR and KRAS mutations were not predictive of response to cetuximab.
PURPOSE: Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase have demonstrated modest anticancer activity in advanced bronchioloalveolar carcinoma (BAC). We conducted a phase II study to evaluate cetuximab for the treatment of advanced BAC. PATIENTS AND METHODS: Patients with advanced-stage pure BAC or adenocarcinoma with BAC features, fewer than two prior chemotherapy regimens, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 were eligible. Those with prior EGFR inhibitor therapy were excluded. Cetuximab was given as a weekly intravenous infusion at 250 mg/m(2) after an initial loading dose of 400 mg/m(2) in week 1. The primary end point was determination of response rate. EGFR and KRAS mutations were evaluated by pyrosequencing. RESULTS: Seventy-two patients were enrolled and 68 met eligibility requirements. Characteristics of patients included median age, 71 years; sex, 57% females; PS 0 or 1, 88% of patients; and smoking status, 19% never-smokers. Central pathology review confirmed the diagnosis in 45 of 49 available specimens. Approximately 50% of patients received more than two cycles of therapy (> 8 weeks). Skin rash was the most common toxicity (grade 3, 15%). The confirmed response rate was 7%, and stable disease was observed in 35%. The median survival and progression-free survival were 13 and 3.3 months, respectively. Only one of the six patients with an EGFR mutation and one of the seven patients with a KRAS mutation had a partial response. CONCLUSION:Cetuximab was associated with modest efficacy in patients with advanced BAC, despite a low response rate. EGFR and KRAS mutations were not predictive of response to cetuximab.
Authors: O S Breathnach; D J Kwiatkowski; D M Finkelstein; J Godleski; D J Sugarbaker; B E Johnson; S Mentzer Journal: J Thorac Cardiovasc Surg Date: 2001-01 Impact factor: 5.209
Authors: Mark G Kris; Giuseppe Giaccone; Angela Davies; Masahiro Fukuoka; David H Garfield; Jacek Jassem; Elisabeth A Quoix; Alan B Sandler; Giorgio V Scagliotti; Jan P Van Meerbeeck; Howard West Journal: J Thorac Oncol Date: 2006-11 Impact factor: 15.609
Authors: Vincent A Miller; Gregory J Riely; Maureen F Zakowski; Allan R Li; Jyoti D Patel; Robert T Heelan; Mark G Kris; Alan B Sandler; David P Carbone; Anne Tsao; Roy S Herbst; Glenn Heller; Marc Ladanyi; William Pao; David H Johnson Journal: J Clin Oncol Date: 2008-03-20 Impact factor: 44.544
Authors: Shuji Ogino; Jeffrey A Meyerhardt; Natsumi Irahara; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531
Authors: Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier Journal: Lancet Date: 2009-05-02 Impact factor: 79.321
Authors: Derick H M Lau; James Moon; Angela M Davies; Rachel E Sanborn; Fred R Hirsch; Wilbur A Franklin; Janet C Ruzich; Mary W Redman; David R Gandara Journal: Clin Lung Cancer Date: 2013-02-14 Impact factor: 4.785
Authors: Suresh S Ramalingam; Angela M Davies; Jeffrey Longmate; Martin J Edelman; Primo N Lara; Everett E Vokes; Miguel Villalona-Calero; Barbara Gitlitz; Karen Reckamp; Ravi Salgia; John J Wright; Chandra P Belani; David R Gandara Journal: J Thorac Oncol Date: 2011-10 Impact factor: 15.609
Authors: Dirk Van Raemdonck; Robin Vos; Jonas Yserbyt; Herbert Decaluwe; Paul De Leyn; Geert M Verleden Journal: J Thorac Dis Date: 2016-11 Impact factor: 2.895